With the development of medical science and technology, the treatment technology of rheumatic diseases is improving, especially the application of biological agents, which has revolutionized the treatment of rheumatic diseases. Over time, biologics such as etanercept, abciximab, infliximab and CD20 monoclonal antibody have gradually changed from unfamiliar “foreign products” to familiar rheumatologic drugs. Biologics are antagonistic drugs targeting specific disease-causing molecules, which block a certain part of the disease through “targeted therapy”, thus stopping or delaying the process of disease onset and development. Unlike traditional small molecule drugs, biologics are biomolecules manufactured by bioengineering methods. In the past decade, the application of biologics in rheumatic diseases represented by rheumatoid arthritis and ankylosing spondylitis has made a major breakthrough, which has substantially improved the clinical efficacy of rheumatic diseases. In such a context, rheumatism, a traditional area of strength of TCM, is facing a certain test. Will TCM lose all its advantages and shrink increasingly because of the application of biological agents? What is the development direction of TCM rheumatology under the new treatment situation? How can TCM continue to give full play to its inherent advantages for the benefit of rheumatism patients? First of all, I think we must affirm the therapeutic effect of biological agents, whose efficacy is supported by a large number of well-designed clinical trials both at home and abroad, and which are gradually recognized by doctors and patients with clinical practice. Not to face up to its role or even unwarranted denigration, is tantamount to cover up the ears of the bell, Shu dog barking at the sun. As a rheumatology department of a hospital combining Chinese and Western medicine, we accepted and used biologics at the early stage of their introduction into China and accumulated rich experience in clinical practice. In this process, we have learned that the application of biologics not only does not weaken TCM, but also gives TCM new room for application. We know that the most common side effect of biologics in rheumatic disease treatment is increased chance of infection. Take the most commonly used biologic agent for rheumatoid arthritis, tumor necrosis factor antagonist, as an example. Patients with rheumatoid arthritis are susceptible to tuberculosis (about twice the rate of the general population), and the use of tumor necrosis factor antagonists can further increase the prevalence of tuberculosis (about four times the rate of the general population); such drugs can also worsen the symptoms and viremia of hepatitis B, so these drugs are not used in patients with active tuberculosis and hepatitis B infection. In addition, a small number of patients are at risk of inducing exacerbation of infections, including bacterial, viral or fungal infections. Therefore, in addition to anti-tuberculin test, chest X-ray and hepatitis virus test for routine screening before using tumor necrosis factor antagonists, the occurrence of infection should be prevented during the treatment. At this time, it is a wise choice if we apply TCM to regulate immunity and improve the body quality to prevent infection. In addition, although there is no reliable evidence suggesting that anti-tumor necrosis factor will increase the incidence of lymphoma and other malignant tumors or make the original solid tumors recur, in theory the drug can increase the risk of tumor occurrence. Therefore, the combination with TCM herbal medicine to nourish the righteousness and prevent tumors also reflects the TCM treatment idea of “prevention before illness”. Biological agents also face the problem of “neutralizing antibodies” in the process of use, the so-called “neutralizing antibodies” are the “anti-drug antibodies” of the body against the drug. The “neutralizing antibodies” will offset the blood concentration of biological agents and reduce the efficacy of the drugs. Chinese herbal medicine can reduce the “neutralizing antibodies” or reduce their effect on drugs by adjusting immunity and inhibiting antigenic antibody reactions. Finally, in view of the national situation in China, most patients’ financial situation cannot support long-term treatment with more expensive biologics. Therefore, after a period of treatment with biologics, patients can continue to use TCM for maintenance treatment, which is an alternative option in line with China’s national conditions. In conclusion, TCM is still promising in the treatment of rheumatic diseases where biologics are gradually and widely used, and the combination of Chinese and Western medicine in the treatment of rheumatic diseases is bound to bring the gospel of recovery to the majority of rheumatic patients, especially those with rheumatoid arthritis and ankylosing spondylitis.